B7-H3 Antibody–Drug Conjugates in Oncology: Clinical Progress, Competitive Positioning, and Strategic Landscape (2025–2026)

Biological and Clinical Rationale

B7-H3, also designated CD276 or B7RP-2, is a transmembrane glycoprotein belonging to the B7 immunoregulatory family. Unlike classical immune checkpoint molecules such as PD-L1 and CTLA-4, B7-H3 operates through incompletely characterized signaling pathways, simultaneously suppressing anti-tumor immunity and promoting tumor cell survival. Mechanistically, B7-H3 inhibits T-cell proliferation and cytokine production (interleukin-2, interferon-γ, perforin, and granzyme B), suppresses natural killer cell and dendritic cell activity, expands immunosuppressive regulatory T cells (FOXP3+), and interacts with key intracellular oncogenic pathways including PI3K/Akt/mTOR, JAK/STAT, NF-κB, and MAPK 810. Beyond immune evasion, B7-H3 promotes metabolic reprogramming, angiogenesis, and epithelial-to-mesenchymal transition, conferring a multifaceted survival advantage to malignant cells 10.

B7-H3 is broadly overexpressed across solid tumor types—including non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), prostate cancer, breast cancer, head and neck squamous cell carcinoma (HNSCC), melanoma, gliomas, renal cell carcinoma, gastrointestinal tumors, and pediatric malignancies—while its expression in most normal adult tissues is relatively restricted 8. High B7-H3 expression has been associated with aggressive tumor biology, advanced stage, and worse prognosis 13. In pediatric CNS tumors, B7-H3 protein was detected in 95.6% of medulloblastoma samples versus only 14.3% of non-tumor brain tissue, with high expression correlating with worse overall survival and metastatic disease at diagnosis 13. In pleural mesothelioma, membranous B7-H3 expression was detected in 86% of a large European cohort 12. These features collectively establish B7-H3 as an attractive ADC target: broad tumor coverage, limited normal-tissue expression, and biological relevance across multiple oncogenic programs.

Key antibody–drug conjugate (ADC) design considerations for B7-H3–directed agents include: (1) antibody specificity to the 4IgB7-H3 isoform preferentially expressed on tumor cells; (2) linker choice—cleavable peptide linkers (tetrapeptide-based, seco-DUBA, GlycoConnect™) or tumor microenvironment-activatable linkers (TMALIN®); (3) payload class, predominantly topoisomerase I (TOP1) inhibitors such as exatecan derivatives (DXd) or DNA-alkylating duocarmycins; (4) drug–antibody ratio (DAR) homogeneity via site-specific conjugation; and (5) the bystander effect, by which released payload can kill adjacent antigen-negative tumor cells, potentially enhancing efficacy in heterogeneous tumors 79.

Table 1: B7-H3 ADC Pipeline Candidates (as of July 2026)

Abbreviations: ES-SCLC, extensive-stage small-cell lung cancer; mCRPC, metastatic castration-resistant prostate cancer; ESCC, esophageal squamous cell carcinoma; sqNSCLC, squamous NSCLC; NPC, nasopharyngeal carcinoma; OC, ovarian cancer; BC, breast cancer; CC, cervical cancer; EC, endometrial cancer; HNSCC, head and neck squamous cell carcinoma; IST, investigator-sponsored trial; ODD, orphan drug designation; PRIME, EMA Priority Medicines; TOP1i, topoisomerase I inhibitor.

Clinical Trial Progress and Medical Interpretation

Extensive-Stage Small-Cell Lung Cancer: The Lead Indication

Ifinatamab deruxtecan (I-DXd) has generated the most mature clinical dataset in ES-SCLC. The IDeate-Lung01 phase 2 trial enrolled 187 patients with pretreated ES-SCLC across Asia, Europe, and North America. At the randomized dose-optimization phase (8 mg/kg vs. 12 mg/kg IV Q3W), the 12 mg/kg dose achieved a BICR-assessed objective response rate (ORR) of 54.8% (95% CI 38.7–70.2) versus 26.1% (95% CI 14.3–41.1) at 8 mg/kg, with disease control rates of 90.5% and 80.4%, median progression-free survival (PFS) of 5.5 and 4.2 months, and median overall survival (OS) of 11.8 and 9.4 months, respectively 2. A notably important exploratory finding was intracranial activity: CNS ORR reached 56% in patients with brain target lesions, addressing a critical unmet need in SCLC management 2. The 12 mg/kg dose was selected for expansion based on superior activity. On April 13, 2026, the FDA accepted the BLA with Priority Review and set a PDUFA date of October 10, 2026, which—if approved—would represent the first B7-H3-directed ADC regulatory clearance globally 15.

SYS6043 (CSPC Megalith) demonstrated broad and striking pan-tumor activity in a phase 1/2 trial of 502 patients. In heavily pretreated SCLC (n=50), ORR was 64.0% (DCR 92.0%); at 6 mg/kg Q3W (n=28), ORR reached 75.0%, including one complete response. Response rates in breast cancer (ORR 83.8%), non-squamous NSCLC (57.1%), ovarian cancer (46.2%), cervical cancer (38.5%), nasopharyngeal carcinoma (37.9%), and endometrial cancer (30.0%) underline the pan-tumor potential of B7-H3 targeting 418. TRAEs occurred in 94.2% of patients (grade ≥3 in 28.5%), with anemia, nausea, leukopenia, and neutropenia as the most common events 18.

HS-20093 received FDA Breakthrough Therapy Designation for ES-SCLC in August 2024, with GSK reporting that the ARTEMIS-008 phase 3 trial met its primary OS endpoint in July 2026 16. In NSCLC (ARTEMIS-001, 167 patients), ORR was 33.3% at 8 mg/kg and 10.7% at 10 mg/kg in non-squamous NSCLC without actionable genomic alterations; the lower ORR at 10 mg/kg relative to 8 mg/kg may reflect reduced dose intensity from higher toxicity at the elevated dose level; grade 1/2 ILD occurred in 2.2% at 8 mg/kg, with no grade ≥3 ILD 16.

Prostate Cancer: Multiple Agents, Differentiated Therapeutic Indices

In the mCRPC setting, three B7-H3 ADCs have reported phase 2 data. DB-1311/BNT324 showed a confirmed ORR of 30.8% and DCR of 95.3% in 43 evaluable CRPC patients, with a 6-month radiographic PFS rate of 86.6% and no treatment-related deaths; discontinuations due to TRAEs were only 6.2%, suggesting a potentially favorable therapeutic index 26. YL201 (n=82, mCRPC, median follow-up 12.2 months) achieved PSA50 response 38.5%, ORR 29.5%, and median radiographic PFS of 9.1 months; notably, no ILD/pneumonitis was observed and treatment discontinuation due to TRAEs was only 1.2% 5. HS-20093 (ARTEMIS-003, 50 Chinese patients with mCRPC) showed cORR 33.3% and DCR 87.9%, with a 9-month rPFS rate of 55.7%, though grade ≥3 TRAEs occurred in 54.0% 17.

By contrast, vobramitamab duocarmazine (MacroGenics), a duocarmycin-based B7-H3 ADC evaluated in the TAMARACK phase 2 trial (N=176 dosed, mCRPC), achieved 6-month radiographic PFS of ~69–70% and ORR up to 40.6% at 2.7 mg/kg, but was discontinued after 11 treatment-related deaths (6.3% of 176 patients) 7. This safety signal highlights that payload selection is critical: duocarmycin DNA-alkylating agents carry a substantially different toxicity profile than TOP1-inhibitor payloads, and the benefit-risk balance must be rigorously established before clinical advancement.

Table 2: Key B7-H3 ADC Clinical Trial Outcomes (Selected, 2025–2026)

NR = not reached; AGA = actionable genomic alterations; ARSI = androgen receptor signaling inhibitor; BC = breast cancer; OC = ovarian cancer.

Competitive and Translational Context

B7-H3 ADCs occupy a distinctive niche relative to established oncology ADC targets. HER2-directed agents (e.g., trastuzumab deruxtecan), TROP2-directed agents (e.g., datopotamab deruxtecan, sacituzumab govitecan), Nectin-4 (enfortumab vedotin), FRα (mirvetuximab soravtansine), and HER3 (patritumab deruxtecan) are each limited by biomarker prevalence, generally requiring companion diagnostic confirmation 3. B7-H3, by contrast, is expressed across a broader spectrum of solid tumors—including histologies where these targets are absent or rare—and may support pan-tumor or histology-agnostic development strategies 38. However, the absence of a standardized companion diagnostic for B7-H3 remains a key differentiation challenge and an active area of translational investigation 19.

Compared with other B7-H3-targeting modalities, ADCs offer manufacturing scalability and established regulatory pathways compared with CAR-T cells, and deliver direct cytotoxic payload beyond what monoclonal antibodies alone can achieve. Radioimmunotherapy with omburtamab (¹³¹I-8H9), a radiolabeled anti-B7-H3 antibody, has demonstrated 3-year OS of 57% in pediatric CNS/leptomeningeal disease, providing clinical validation of B7-H3 as a targetable antigen 7. Immune-checkpoint targeting drug conjugates (IDCs) represent an emerging conceptual framework that combines checkpoint antibodies with cytotoxic payloads, with multiple B7-H3 IDCs now in early-phase trials 3. Preclinical work in glioblastoma models has shown that AURKA inhibition combined with anti-B7-H3 antibody reduces tumor size and promotes CD8+ T-cell infiltration, suggesting rational basis for future combination ADC trials in CNS malignancies 9.

Table 3: Notable 2025–2026 B7-H3 ADC Deals and Regulatory Milestones

Deal Interest and Strategic Implications

The aggregate deal value committed to B7-H3 ADC programs through mid-2026 is substantial: Merck's co-development terms for I-DXd, Roche's $570 million upfront for YL201, GSK's $185 million for HS-20093, and BioNTech's $170 million for DB-1311 collectively represent billions in committed capital and milestone exposure 2021. These transactions reflect several overlapping investment theses. First, B7-H3's pan-tumor expression provides a broader commercial addressable market than single-indication targets. Second, TOP1-inhibitor payloads (DXd, exatecan derivatives) have clinical validation through approved agents, reducing platform risk. Third, Chinese innovation—Hansoh, MediLink, DualityBio, CSPC—has proven clinically competitive, offering attractive licensing opportunities for global pharma at mid-stage price points. Fourth, the absence of an approved B7-H3 ADC through mid-2026 represents genuine first-mover advantage for programs reaching regulatory decisions in late 2026 and 2027.

The discontinuation of vobramitamab duocarmazine's internal program at MacroGenics due to treatment-related mortality underscores that payload selection is not interchangeable: duocarmycin's DNA-alkylating mechanism requires careful therapeutic-window optimization, and the field is closely monitoring whether the TOP1-inhibitor class offers a more favorable profile for this target 7.

Forward-Looking Outlook and Evidence Gaps

Major catalysts anticipated after the July 2026 cut-off include:

1. FDA approval decision for I-DXd (October 10, 2026): Potential first approval of a B7-H3 ADC; would validate the target class and accelerate competitor development timelines 15.
2. HS-20093 phase 3 data: ARTEMIS-008 met its primary OS endpoint in July 2026; full data presentation expected at an upcoming oncology congress, alongside GSK's global phase 1/2 expansion 16.
3. YL201 phase 3 readouts: Phase 3 registrational trials for SCLC and nasopharyngeal carcinoma in China are underway; Roche-led global development accelerates non-China timelines 520.
4. SYS6043 phase 3 initiation: The broad efficacy signal in 502 enrolled patients supports phase 3 advancement in SCLC, ovarian cancer, and potentially breast cancer 418.
5. Combination trial expansion: I-DXd is being evaluated with gocatamig (a DLL3-targeted T-cell engager) in relapsed/refractory ES-SCLC; additional combination signals with checkpoint inhibitors are expected across multiple B7-H3 programs 7.
6. Biomarker standardization: B7-H3 expression quantification—immunohistochemistry H-score thresholds, membrane versus cytoplasmic expression—remains unstandardized. YL201 phase 2 mCRPC data showed no association between B7-H3 H-score and response 5, suggesting patient selection may not require a companion diagnostic, but this requires prospective validation.
7. Pediatric development: B7-H3's near-universal expression in medulloblastoma (95.6%) and neuroblastoma, combined with high unmet need, represents a logical expansion frontier, though no clinical ADC data were identified in the retrieved materials for these histologies 13.

Important evidence gaps in the current dataset include absence of payload/linker detail for several agents (SYS6043, HS-20093 linker undisclosed), lack of head-to-head comparative data, limited data in breast cancer, HNSCC, and pediatric populations for most ADCs, and absence of long-term OS data for most phase 2 programs. Cross-trial efficacy comparisons are methodologically constrained by differing tumor types, prior therapy lines, dosing schedules, and endpoint maturity.

Summary

B7-H3 antibody–drug conjugates have rapidly emerged as a clinically validated and commercially prioritized class within oncology during 2025–2026. Ifinatamab deruxtecan stands at the threshold of becoming the first approved B7-H3 ADC, with FDA Priority Review and a PDUFA date of October 10, 2026. SYS6043's pan-tumor activity across eight histologies, YL201's Roche partnership valued at $570 million upfront, and HS-20093's OS endpoint achievement in SCLC collectively confirm a field maturing rapidly from exploratory biology to regulatory-stage development. Safety differentiation—particularly the contrast between TOP1-inhibitor profiles and duocarmycin-related treatment-related mortality—will inform both clinical practice and future ADC design. Biomarker strategy, combination approaches, and pediatric development remain areas where the field must advance to fully realize B7-H3's broad therapeutic potential through 2027 and beyond 38.